Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Candida albicans | Involved in protection against oxidative damage | Starlite/ChEMBL | References |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium leprae | CARBONIC ANHYDRASE (CARBONATE DEHYDRATASE) (CARBONIC DEHYDRATASE) | 0.0275 | 0 | 0.5 |
Schistosoma mansoni | integrin alpha-ps | 0.0603 | 0.1823 | 0.3065 |
Loa Loa (eye worm) | hypothetical protein | 0.1057 | 0.4342 | 0.4298 |
Echinococcus multilocularis | integrin alpha ps | 0.0603 | 0.1823 | 0.4231 |
Mycobacterium ulcerans | carbonic anhydrase | 0.0275 | 0 | 0.5 |
Loa Loa (eye worm) | integrin beta-2 | 0.0759 | 0.2687 | 0.263 |
Schistosoma mansoni | integrin alpha-ps | 0.0314 | 0.0216 | 0.0363 |
Loa Loa (eye worm) | hypothetical protein | 0.0743 | 0.2597 | 0.2539 |
Echinococcus multilocularis | integrin alpha ps | 0.0603 | 0.1823 | 0.4231 |
Echinococcus multilocularis | integrin beta 2 | 0.0556 | 0.1558 | 0.3588 |
Echinococcus multilocularis | integrin alpha 3 | 0.1032 | 0.4204 | 1 |
Schistosoma mansoni | integrin beta subunit | 0.0437 | 0.0896 | 0.1506 |
Echinococcus granulosus | integrin beta 2 | 0.0556 | 0.1558 | 0.3588 |
Schistosoma mansoni | integrin alpha | 0.1346 | 0.595 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0314 | 0.0216 | 0.014 |
Brugia malayi | Integrin alpha pat-2 precursor | 0.1346 | 0.595 | 1 |
Leishmania major | carbonic anhydrase family protein, putative | 0.0275 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.1018 | 0.4128 | 0.4082 |
Schistosoma mansoni | hypothetical protein | 0.0289 | 0.0078 | 0.013 |
Echinococcus granulosus | integrin alpha ps | 0.0603 | 0.1823 | 0.4231 |
Entamoeba histolytica | carbonic anhydrase, putative | 0.0275 | 0 | 0.5 |
Brugia malayi | Integrin alpha cytoplasmic region family protein | 0.1018 | 0.4128 | 0.4415 |
Echinococcus granulosus | integrin alpha 3 | 0.1032 | 0.4204 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Ki (binding) | = 52 nM | inhibition of Candida albicans recombinant Nce103 after 15 mins by stopped-flow CO2 hydration assay | ChEMBL. | 20299219 |
Kinact (binding) | = 6.2 10'6nM | Inhibition of human recombinant CA3 by stopped-flow CO2 hydration method | ChEMBL. | 18819811 |
Kinact (binding) | = 8.5 nM | Inhibition of human recombinant CA14 by stopped-flow CO2 hydration method | ChEMBL. | 18819811 |
Kinact (binding) | = 9.2 nM | Inhibition of human recombinant CA2 by stopped-flow CO2 hydration method | ChEMBL. | 18819811 |
Kinact (binding) | = 53 nM | Inhibition of mouse recombinant CA15 by stopped-flow CO2 hydration method | ChEMBL. | 18819811 |
Kinact (binding) | = 70 nM | Inhibition of human recombinant CA12 catalytic domain by stopped-flow CO2 hydration method | ChEMBL. | 18819811 |
Kinact (binding) | = 72 nM | Inhibition of human recombinant CA7 by stopped-flow CO2 hydration method | ChEMBL. | 18819811 |
Kinact (binding) | = 73 nM | Inhibition of human recombinant CA9 catalytic domain by stopped-flow CO2 hydration method | ChEMBL. | 18819811 |
Kinact (binding) | = 311 nM | Inhibition of human recombinant CA1 by stopped-flow CO2 hydration method | ChEMBL. | 18819811 |
Kinact (binding) | = 743 nM | Inhibition of human recombinant CA5A by stopped-flow CO2 hydration method | ChEMBL. | 18819811 |
Kinact (binding) | = 816 nM | Inhibition of mouse recombinant CA13 by stopped-flow CO2 hydration method | ChEMBL. | 18819811 |
Kinact (binding) | = 844 nM | Inhibition of human recombinant CA5B by stopped-flow CO2 hydration method | ChEMBL. | 18819811 |
Kinact (binding) | = 5570 nM | Inhibition of human recombinant CA6 by stopped-flow CO2 hydration method | ChEMBL. | 18819811 |
Kinact (binding) | = 6140 nM | Inhibition of human recombinant CA4 by stopped-flow CO2 hydration method | ChEMBL. | 18819811 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
2 literature references were collected for this gene.